Immunotherapy in the treatment of lymphoma

作     者：Lazar S Popovic Gorana Matovina-Brko Maja Popovic Milica Popovic Ana Cvetanovic Ivan Nikolic Biljana Kukic Dragana Petrovic 

作者机构：Department for Medical OncologyOncology Institute of VojvodinaUniversity of Novi SadNovi Sad 21000Serbia Department for Medical OncologyOncology Institute of VojvodinaNovi Sad 21000Serbia Department for Nephrology and Clinical ImmunologyClinical Center of VojvodinaUniversity of Novi SadNovi Sad 21000Serbia Department for Medical OncologyClinical Center of NisUniversity of NisNis 18000Serbia 

出 版 物：《World Journal of Stem Cells》 (世界干细胞杂志（英文版）（电子版）)

年 卷 期：2021年第13卷第6期

页      面：503-520页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Immunotherapy Receptors Chimeric antigen Antibodies Monoclonal Immunoconjugates Hodgkin disease Lymphoma Large B-cell Diffuse 

摘      要：Relapsed or refractory non-Hodgkin’s lymphomas,especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat *** who do not respond to initial therapy or experience relapse are treated with salvage regimens,and if eligible for aggressive therapy,treatment is continued with high-dose chemotherapy and autologous stem cell *** therapy options can cure substantial numbers of patients,however for some it is still an uncurable *** new drugs and cell therapies are being investigated for the treatment of relapsed or refractory *** types of immunotherapy options have shown promising results,and some have already become the standard of ***,we review immunotherapy options for the treatment of lymphoma and discuss the results,positions,practical aspects,and future directions of different drugs and cellular therapies for the treatment of this disease.